Access Aims to Develop Oral Drug-Delivery Technology for RNAi Therapeutics
February 11, 2010
Access Aims to Develop Oral Drug-Delivery Technology for RNAi Therapeutics
The technology, dubbed Cobalamin, is based on the body's natural vitamin B12 uptake mechanism, and involves merging a polymer and active pharmaceutical ingredient to make a nanoparticle, which is then coated with the vitamin.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Samyang, Access Pharmaceuticals Ink RNAi-Delivery Research Deals
April 14, 2011 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
February 28, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Leonardo Receives Second Half of $2.5M Grant
November 17, 2011 / Gene Silencing News